EQS-News: Vycor Medical, Inc.: Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2026

Vycor Medical, Inc. (OTCQB: VYCO) reported revenue of $418.3k for the three months ended June 30, 2026, down 16% from 2025, and $876.8k for six months, down 6%. Vycor Medical (VBAS) revenue fell 17% (quarter) and 7% (six months). GAAP operating profit was $6.9k (quarter) and $52.7k (six months).

Original reporting
Published Aug 14, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VYCO
Neutral
medium confidence
Mentioned
$VYCO
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$VYCONeutralMed
01

Why it matters

The earnings release is primarily a financial performance update: revenue declined year over year, international sales weakness is emphasized, and operating profit trends diverge between 3-month and 6-month periods.

02

Market read

Traders can reassess near-term risk for VYCO based on disclosed revenue contraction and operating profit trajectory, plus ongoing VBAS clinical publication momentum.

03

What to watch

The release emphasizes non-GAAP adjustments and clinical paper counts but does not disclose cash balance, liquidity, or forward guidance, which are often the key drivers for OTCQBs after earnings.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release dated Aug 14, 2026

Background

Vycor Medical is an OTCQBs-listed medical device company with VBAS (ViewSite Brain Access System) and a development-stage NovaVision therapy program.

Company-level read

Ticker impact

$VYCONeutralMedium confidence
Context

Vycor reported Q2 and 6M ended June 30, 2026 results, including revenue declines and GAAP/non-GAAP operating profit changes.

Expected impact

Near-term trading bias likely neutral to slightly negative unless investors focus on the six-month GAAP operating profit improvement and ongoing VBAS clinical publication momentum.

Evidence & confidence

Key disclosed datapoints are revenue down 16% (3M) and 6% (6M), with GAAP operating profit of $6.9k (3M) vs $51.1k and $52.7k (6M) vs $38.3k. The article provides no guidance or balance-sheet/cash runway details, limiting conviction on direction.

Market effects

Provides a datapoint on demand volatility for neurosurgical access systems, with international orders described as lumpy.

Highlights that the revenue decline is primarily from international markets for both the 3-month and 6-month periods.

Limited broader market relevance; mainly company-specific read-through for small-cap medical device investors.

Counterpoint

Investors may discount the international revenue weakness as quarter-to-quarter order timing and instead emphasize the six-month GAAP operating profit improvement and continued VBAS peer-reviewed publications.

Key entities

  • Vycor Medical, Inc.

    Reports financial results for the three and six months ended June 30, 2026, including VBAS revenue declines and operating profit changes.

  • ViewSite Brain Access System (VBAS)

    Primary revenue driver; article cites revenue declines and three new peer-reviewed studies published during 2026 to date.

  • NovaVision

    Development-stage division; article reports small revenue increases for the three and six months ended June 30, 2026.

Related articles

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.